G1 Therapeutics Gross Profit vs. Return On Asset

GTHXDelisted Stock  USD 7.15  0.00  0.00%   
Based on G1 Therapeutics' profitability indicators, G1 Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess G1 Therapeutics' ability to earn profits and add value for shareholders.
For G1 Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of G1 Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well G1 Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between G1 Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of G1 Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

G1 Therapeutics Return On Asset vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining G1 Therapeutics's current stock value. Our valuation model uses many indicators to compare G1 Therapeutics value to that of its competitors to determine the firm's financial worth.
G1 Therapeutics is rated # 4 in gross profit category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the G1 Therapeutics' earnings, one of the primary drivers of an investment's value.

GTHX Return On Asset vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

G1 Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
47.55 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

G1 Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.19
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

GTHX Return On Asset Comparison

G1 Therapeutics is currently under evaluation in return on asset category among its peers.

G1 Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in G1 Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, G1 Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of G1 Therapeutics' change in net profit over the period of time. It can combine multiple indicators of G1 Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.

GTHX Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on G1 Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of G1 Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the G1 Therapeutics' important profitability drivers and their relationship over time.

Use G1 Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if G1 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in G1 Therapeutics will appreciate offsetting losses from the drop in the long position's value.

G1 Therapeutics Pair Trading

G1 Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to G1 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace G1 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back G1 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling G1 Therapeutics to buy it.
The correlation of G1 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as G1 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if G1 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for G1 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your G1 Therapeutics position

In addition to having G1 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large & Mid Caps ETFs Thematic Idea Now

Large & Mid Caps ETFs
Large & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Consideration for investing in GTHX Stock

If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like